Cancer Incidence
About 20 million new cancer cases are diagnosed worldwide each year. Cancer is the second-leading cause of death globally after cardiovascular disease, and the leading cause in many advanced economies under age 70. Lung, breast, colorectal, prostate and stomach are the top five cancers globally. Incidence rises with age — most of the future cancer burden will come from population aging, not rising age-specific risk.
Key insights
Aging dominates the rise
The crude global cancer rate is rising fast, but age-standardised rates have been roughly flat or slowly declining in advanced economies. Most of the headline growth comes from population aging — people now live long enough to develop the cancers that age-related cellular damage produces. Where rates have fallen at given ages, it has been from reduced smoking (lung cancer), better screening (colorectal, cervical), and reduced infection-related cancers (stomach, liver, cervical).
Tobacco still drives the largest single cause
Lung cancer remains the top cancer killer globally with ~1.8 million deaths a year. About 85% are attributable to tobacco. As smoking declines in advanced economies, lung cancer is following with a 20-year lag — US male age-standardised lung cancer mortality has halved since 1990. In countries where smoking is still rising (Indonesia, parts of Africa) lung cancer is projected to grow for decades.
Country patterns reveal local risk factors
Liver cancer is exceptionally common in East Asia and sub-Saharan Africa (hepatitis B infection and aflatoxin exposure). Stomach cancer is highest in Japan and Korea (Helicobacter pylori infection, high-salt diet). Cervical cancer rates in sub-Saharan Africa are 5–10× European rates (lack of HPV vaccination and screening). Each pattern points to a preventable cause — the geography of cancer is partly the geography of unmet prevention opportunities.
Top cancers by incidence (2022)
New cases per year, millions
Key Finding: Lung, breast, colorectal, prostate and stomach together account for ~50% of cancers.
Age-standardised cancer incidence — selected countries
Cases per 100,000 (both sexes, all cancers)
Key Finding: Australia and Northern Europe top the league — partly real risk, partly more thorough recording and screening detection.
Methodology & caveats
Incidence vs mortality vs prevalence
Incidence = new cases in a year. Mortality = deaths in a year. Prevalence = people living with cancer at a point in time. The three differ — a high-incidence, high-survival cancer (prostate, thyroid) has high prevalence; a high-incidence, low-survival cancer (pancreatic, lung) has lower prevalence relative to incidence.
Age-standardisation
Crude incidence rates compare poorly across countries with different age structures. Age-standardised rates apply each country's age-specific rates to a common reference population (usually the WHO World Standard Population). Cross-country comparisons should always use age-standardised rates, not crude figures.
Detection vs incidence
Higher screening detection can drive measured incidence without changing underlying risk — thyroid cancer rates have risen many-fold in South Korea after ultrasound screening became routine. Cancer registries vary in coverage, completeness and methodology; GLOBOCAN harmonises but cannot fully correct for this. Treat incidence comparisons across very different health systems with appropriate caution.